India's Richest People 2026 edition · 1 director · Source: Hurun India
- #1,113 Prakash Amrut Mody ₹2,300 Cr
Market Cap
₹3,553 Cr
UNICHEMLAB · NSE
Share Price
₹487.75
-3.35% today
Revenue
₹2,202 Cr
FY 2025-26 · +4.3% YoY
EBITDA
₹111 Cr
Margin 5.0%
Net Profit
₹81.89 Cr
FY 2025-26 · -40.1% YoY
P/E (TTM)
29.1x
P/B 1.3x
ROE
3.2%
ROCE 4.1%
Debt / Equity
0.19
Interest cover -216.2x
About Unichem Laboratories Limited
Data last updated:
Unichem Laboratories Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 22 August 1962 and has been in existence for over 64 years.
Its director Prakash Amrut Mody is #1,113 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L99999MH1962PLC012451. Its GSTIN is 27AAACU0551B1ZW (Maharashtra). The company holds 26 GST registrations, of which 6 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 506690 and NSE: UNICHEMLAB.
The company has an authorised share capital of ₹50 Cr and a paid-up capital of ₹14.08 Cr. It is led by directors including Pabitrakumar Kalipada Bhattacharyya (Managing Director) and Prakash Amrut Mody.
Its last annual general meeting (AGM) was held on 04 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 47 Kandivli Industrial Estate, Mumbai, Maharashtra, India – 400067.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹2,201.85 Cr, a growth of 4.3% compared to the previous year. For the same year it recorded a net profit of ₹81.89 Cr (net margin 3.7%) and EBITDA of ₹110.51 Cr (EBITDA margin 5%). The net worth stands at ₹2,717.44 Cr (up 10.9% YoY). Total assets are valued at ₹3,246.65 Cr (up 10% YoY).
The company has about 3,635 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Unichem Laboratories and Unichem Labs. As per MCA filings, the company has open charges of ₹236 Cr and satisfied charges of ₹249.07 Cr on record. Court records list 263 cases involving the company, including 169 filed by the company and 94 filed against it; 41 cases are pending. The company has 14 deals on record (9 market trades, 2 secondary share transfers, 2 acquisitions), with disclosed funding of ₹56.32 Cr; the latest was in July 2026. Its 10 peer companies in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 5 smaller; the largest is Aarti Drugs Limited with revenue of ₹2,403.39 Cr. The company has 30 MSME Form 1 returns on record between 2014 and 2024, listing 197 overdue payments to 63 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website unichemlabs.com.
Company details
CIN L99999MH1962PLC012451
Registration Number 012451
Incorporation Date 22 August 1962
ROC Mumbai
Listing Status Listed - Listed on NSE (UNICHEMLAB); Listed on BSE (506690)
Company Status Active
Date of Last AGM 04 August 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
Key People
Pabitrakumar Kalipada Bhattacharyya Managing Director Prakash Amrut Mody Director Swati Arvind Patankar Additional Director Recognitions & Rankings of Unichem Laboratories
Contact details
Unichem Laboratories Limited's registered office is in Mumbai, Maharashtra. Its website is unichemlabs.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address47 Kandivli Industrial Estate, Mumbai, Maharashtra, India – 400067
- IndustryPharma, API Manufacturers, Drug Formulation & Development
To see the full contact details of Unichem Laboratories Limited, buy the company report.
Comprehensive company report
Unichem Laboratories Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Unichem Laboratories operates two associated brands: Unichem Laboratories and Unichem Labs. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Branded formulations, APIs, and biosimilars are manufactured. | unichemlabs.com | |
| Pharmaceutical formulations, active pharmaceutical ingredients manufacturing, and related services in India. | unichem-hrp.com |
Business activity
The main business activity of Unichem Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Unichem Laboratories Limited, buy the company report.
Financials of Unichem Laboratories Limited
FY 2025-26 filings availableUnichem Laboratories Limited reported revenue of ₹2,201.85 Cr (up 4.3% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹2,202 Cr
+4.3% YoY
EBITDA
₹111 Cr
-58.3% YoY
Profit After Tax
₹81.89 Cr
-40.1% YoY
Net Worth
₹2,717 Cr
+10.9% YoY
Total Assets
₹3,247 Cr
+10.0% YoY
Total Debt
₹500 Cr
+8.8% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 2,202 | 2,111 | 1,785 | 1,343 | 1,270 | 1,235 | 1,104 |
| Revenue growth | +4.3% | +18.3% | +32.9% | +5.8% | +2.8% | +11.9% | - |
| EBITDA | 111 | 265 | (38.74) | (84.12) | 71.72 | 90.77 | (50.82) |
| EBITDA margin | +5.0% | +12.6% | -2.2% | -6.3% | +5.7% | +7.4% | -4.6% |
| Profit before tax | 292 | 155 | (84.96) | (176) | 21.95 | 51.48 | (48.21) |
| Net profit | 81.89 | 137 | (43.58) | (178) | 31.53 | 26.81 | (86.06) |
| Net profit margin | +3.7% | +6.5% | -2.4% | -13.3% | +2.5% | +2.2% | -7.8% |
| EPS (₹) | 35.91 | 19.53 | (13.32) | (28.72) | 4.70 | 4.88 | (8.55) |
| Balance sheet | |||||||
| Total assets | 3,247 | 2,951 | 2,722 | 2,792 | 3,012 | 2,711 | 2,766 |
| Net worth | 2,717 | 2,451 | 2,438 | 2,435 | 2,618 | 2,557 | 2,531 |
| Total debt | 500 | 460 | 248 | 314 | 349 | 119 | 206 |
| Cash & bank | 295 | 118 | 158 | 185 | 114 | 82.45 | 234 |
| Net working capital | 1,746 | 1,411 | 1,190 | 1,186 | 1,078 | 740 | 889 |
| Cash flow | |||||||
| Cash from operations | 3.64 | (7.02) | 14.00 | (85.09) | (260) | 32.98 | 19.82 |
| Cash from investing | 194 | (242) | 63.31 | 241 | 100 | (65.97) | (35.91) |
| Cash from financing | 1.86 | 184 | (106) | (81.30) | 191 | (121) | (62.30) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 633 | 575 | 521 | 579 | 527 | 587 | 533 | 507 |
| Revenue growth (YoY) | +20.1% | -2.1% | -2.2% | +14.1% | +9.0% | - | - | - |
| Other income | 15.61 | 23.47 | 287 | 20.97 | 6.82 | 9.25 | 13.62 | 8.69 |
| EBITDA | 69.94 | 35.32 | 44.78 | 7.92 | 22.49 | 83.70 | 85.52 | 55.49 |
| EBITDA margin | +11.1% | +6.1% | +8.6% | +1.4% | +4.3% | +14.3% | +16.0% | +10.9% |
| Depreciation | 29.94 | 30.61 | 31.25 | 31.47 | 31.79 | 29.69 | 30.54 | 32.26 |
| Interest | 6.62 | 9.39 | 7.42 | 8.24 | 6.54 | 5.46 | 6.75 | 4.79 |
| Profit before tax | 48.99 | 18.79 | 293 | (10.82) | (9.02) | 57.80 | 61.85 | 27.13 |
| Tax | 7.52 | 7.88 | 29.14 | 1.07 | 1.45 | 4.83 | 4.00 | 2.50 |
| Net profit | 41.47 | 10.91 | 264 | (11.89) | (10.47) | 52.97 | 57.85 | 24.63 |
| EPS (₹) | 5.89 | 1.55 | 37.47 | (1.69) | (1.49) | 7.50 | 8.19 | 3.49 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1,412 | 1,736 | 1,442 | 1,072 | 943 | 1,124 | 904 |
| Revenue growth | -18.6% | +20.4% | +34.5% | +13.7% | -16.1% | +24.3% | - |
| EBITDA | (23.30) | 254 | (74.71) | (206) | (43.55) | 95.48 | (90.61) |
| EBITDA margin | -1.7% | +14.6% | -5.2% | -19.2% | -4.6% | +8.5% | -10.0% |
| Profit before tax | 209 | 183 | (92.18) | (279) | (86.74) | 65.66 | (63.81) |
| Net profit | (15.57) | 159 | (36.24) | (197) | (55.17) | 54.08 | (54.86) |
| Net profit margin | -1.1% | +9.1% | -2.5% | -18.3% | -5.9% | +4.8% | -6.1% |
| EPS (₹) | 22.58 | 23.15 | (13.09) | (42.57) | (7.87) | 7.68 | (8.00) |
| Balance sheet | |||||||
| Total assets | 2,720 | 2,621 | 2,402 | 2,536 | 2,849 | 2,734 | 2,692 |
| Net worth | 2,627 | 2,460 | 2,295 | 2,384 | 2,672 | 2,697 | 2,647 |
| Total debt | 64.08 | 123 | 70.30 | 108 | 132 | 1.48 | 16.71 |
| Cash & bank | 258 | 88.63 | 129 | 157 | 99.03 | 57.59 | 205 |
| Net working capital | 1,234 | 1,098 | 943 | 941 | 837 | 698 | 753 |
| Cash flow | |||||||
| Cash from operations | 52.60 | 72.29 | (41.57) | (117) | (158) | (32.61) | (41.84) |
| Cash from investing | 210 | (176) | 59.61 | 241 | 104 | (72.79) | (35.59) |
| Cash from financing | (70.66) | 38.26 | (48.06) | (61.76) | 95.80 | (45.07) | (21.02) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 366 | 356 | 315 | 357 | 384 | 461 | 448 | 437 |
| Revenue growth (YoY) | -4.7% | -22.8% | -29.7% | -18.3% | -1.4% | - | - | - |
| Other income | 16.72 | 22.22 | 291 | 21.40 | 4.25 | 10.05 | 18.93 | 7.08 |
| Total expenses | 346 | 356 | 314 | 382 | 359 | 386 | 374 | 372 |
| EBITDA | 20.64 | 0.13 | 1.39 | (25.44) | 25.74 | 74.98 | 74.21 | 64.50 |
| EBITDA margin | +5.6% | +0.0% | +0.4% | -7.1% | +6.7% | +16.3% | +16.6% | +14.8% |
| Depreciation | 28.69 | 28.97 | 30.02 | 30.11 | 29.93 | 27.47 | 28.45 | 26.39 |
| Interest | 1.29 | 4.09 | 2.10 | 3.68 | 1.93 | 1.53 | 2.89 | 1.82 |
| Profit before tax | 7.38 | (10.71) | 260 | (37.83) | (1.87) | 56.03 | 61.80 | 43.37 |
| Tax | 1.85 | 4.68 | 43.71 | 2.10 | (0.02) | 4.81 | 14.91 | 0.00 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 22 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 633 | 575 | 521 | 579 | 527 | 587 | 533 | 507 |
| Revenue growth (YoY) | +20.1% | -2.1% | -2.2% | +14.1% | +9.0% | - | - | - |
| Other income | 15.61 | 23.47 | 287 | 20.97 | 6.82 | 9.25 | 13.62 | 8.69 |
| EBITDA | 69.94 | 35.32 | 44.78 | 7.92 | 22.49 | 83.70 | 85.52 | 55.49 |
| EBITDA margin | +11.1% | +6.1% | +8.6% | +1.4% | +4.3% | +14.3% | +16.0% | +10.9% |
| Depreciation | 29.94 | 30.61 | 31.25 | 31.47 | 31.79 | 29.69 | 30.54 | 32.26 |
| Interest | 6.62 | 9.39 | 7.42 | 8.24 | 6.54 | 5.46 | 6.75 | 4.79 |
| Profit before tax | 48.99 | 18.79 | 293 | (10.82) | (9.02) | 57.80 | 61.85 | 27.13 |
| Tax | 7.52 | 7.88 | 29.14 | 1.07 | 1.45 | 4.83 | 4.00 | 2.50 |
| Net profit | 41.47 | 10.91 | 264 | (11.89) | (10.47) | 52.97 | 57.85 | 24.63 |
| EPS (₹) | 5.89 | 1.55 | 37.47 | (1.69) | (1.49) | 7.50 | 8.19 | 3.49 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 2,202 | 2,111 | 1,785 | 1,343 | 1,270 | 1,235 | 1,104 |
| Revenue growth | +4.3% | +18.3% | +32.9% | +5.8% | +2.8% | +11.9% | - |
| Other income | 339 | 35.32 | 99.60 | 38.52 | 47.51 | 50.19 | 92.13 |
| Total expenses | 2,091 | 1,846 | 1,824 | 1,427 | 1,198 | 1,144 | 1,155 |
| Employee cost | 397 | 402 | 403 | 356 | 330 | 307 | 273 |
| EBITDA | 111 | 265 | (38.74) | (84.12) | 71.72 | 90.77 | (50.82) |
| EBITDA margin | +5.0% | +12.6% | -2.2% | -6.3% | +5.7% | +7.4% | -4.6% |
| Depreciation | 125 | 125 | 123 | 113 | 91.17 | 84.36 | 81.67 |
| Interest | 31.59 | 21.03 | 22.66 | 17.31 | 6.11 | 5.12 | 7.85 |
| Profit before tax | 292 | 155 | (84.96) | (176) | 21.95 | 51.48 | (48.21) |
| Tax | 39.54 | 17.07 | 8.80 | 25.86 | (11.09) | 17.15 | 11.97 |
| Net profit | 81.89 | 137 | (43.58) | (178) | 31.53 | 26.81 | (86.06) |
| Net profit margin | +3.7% | +6.5% | -2.4% | -13.3% | +2.5% | +2.2% | -7.8% |
| EPS (₹) | 35.91 | 19.53 | (13.32) | (28.72) | 4.70 | 4.88 | (8.55) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 14.08 | 14.08 | 14.08 | 14.08 | 14.08 | 14.08 | 14.08 |
| Reserves & surplus | 2,703 | 2,437 | 2,424 | 2,421 | 2,604 | 2,543 | 2,517 |
| Shareholders' funds (net worth) | 2,717 | 2,451 | 2,438 | 2,435 | 2,618 | 2,557 | 2,531 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 469 | 430 | 219 | 297 | 330 | 101 | 184 |
| Unsecured loans | 31.37 | 29.80 | 28.37 | 16.65 | 18.79 | 18.47 | 22.47 |
| Total debt | 500 | 460 | 248 | 314 | 349 | 119 | 206 |
| Total liabilities | 3,247 | 2,951 | 2,722 | 2,792 | 3,012 | 2,711 | 2,766 |
| Assets | |||||||
| Gross block | 1,985 | 1,994 | 1,920 | 1,750 | 1,380 | 1,181 | 1,102 |
| Net block | 1,213 | 1,300 | 1,252 | 1,257 | 990 | 884 | 870 |
| Capital work in progress | 100 | 30.67 | 123 | 147 | 494 | 568 | 330 |
| Investments | 0.02 | 0.02 | 1.36 | 1.70 | 264 | 392 | 550 |
| Inventories | 975 | 989 | 736 | 625 | 600 | 538 | 397 |
| Sundry debtors | 829 | 779 | 642 | 589 | 495 | 250 | 390 |
| Cash & bank balances | 295 | 118 | 158 | 185 | 114 | 82.45 | 234 |
| Loans & advances | 99.09 | 144 | 205 | 188 | 175 | 270 | 247 |
| Total current assets | 2,197 | 2,029 | 1,742 | 1,587 | 1,385 | 1,141 | 1,267 |
| Total current liabilities | 451 | 618 | 552 | 401 | 307 | 401 | 379 |
| Net working capital | 1,746 | 1,411 | 1,190 | 1,186 | 1,078 | 740 | 889 |
| Total assets | 3,247 | 2,951 | 2,722 | 2,792 | 3,012 | 2,711 | 2,766 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 89.58 | 155 | 184 | 109 | 77.46 | 232 | 310 |
| Net cash from operating activities | 3.64 | (7.02) | 14.00 | (85.09) | (260) | 32.98 | 19.82 |
| Net cash from investing activities | 194 | (242) | 63.31 | 241 | 100 | (65.97) | (35.91) |
| Net cash from financing activities | 1.86 | 184 | (106) | (81.30) | 191 | (121) | (62.30) |
| Net change in cash | 200 | (65.17) | (29.00) | 74.56 | 31.74 | (154) | (78.40) |
| Closing cash | 295 | 118 | 158 | 185 | 114 | 82.45 | 234 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +4.3% | +18.3% | +32.9% | +5.8% | +2.8% | +11.9% | - |
| EBITDA growth | -58.3% | +783.7% | +54.0% | -217.3% | -21.0% | +278.6% | - |
| PBT growth | +89.1% | +9998.0% | +51.8% | - | -57.4% | +9998.0% | +17.1% |
| Net income growth | -40.1% | +413.6% | +75.5% | -665.2% | +17.6% | +131.2% | - |
| Revenue CAGR (3Y) | +17.9% | +18.5% | +13.1% | +6.8% | +2.5% | +14.9% | +16.5% |
| EBITDA CAGR (3Y) | - | +54.6% | - | +18.3% | - | - | +7.1% |
| Profitability & leverage | |||||||
| Net income margin | +11.5% | +6.5% | -5.3% | -15.1% | +2.6% | +2.8% | -5.5% |
| Return on capital employed | +4.1% | +6.2% | -0.2% | -4.5% | +0.9% | +1.7% | -2.4% |
| Return on net worth | +3.2% | +5.6% | -1.8% | -7.1% | +1.2% | +1.1% | -3.3% |
| Debt / equity | 0.19 | 0.14 | 0.12 | 0.13 | 0.09 | 0.06 | 0.08 |
| Long-term debt / equity | 0.03 | 0.03 | 0.03 | 0.04 | 0.02 | 0.01 | 0.00 |
| Interest cover | -216.22 | 14.99 | -14.00 | -8.76 | -31.41 | 79.88 | -5.92 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.11 | 1.08 | 0.97 | 0.86 | 1.00 | 1.08 | 1.06 |
| Inventory turnover | 2.24 | 2.45 | 2.62 | 2.19 | 2.23 | 2.64 | 3.00 |
| Debtors turnover | 2.74 | 2.97 | 2.90 | 2.48 | 3.41 | 3.86 | 2.67 |
| EPS (₹) | 35.91 | 19.53 | (13.32) | (28.72) | 4.70 | 4.88 | (8.55) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| Book value per share (₹) | 386.00 | 348.10 | 346.35 | 345.89 | 371.90 | 363.16 | 359.54 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 366 | 356 | 315 | 357 | 384 | 461 | 448 | 437 |
| Revenue growth (YoY) | -4.7% | -22.8% | -29.7% | -18.3% | -1.4% | - | - | - |
| Other income | 16.72 | 22.22 | 291 | 21.40 | 4.25 | 10.05 | 18.93 | 7.08 |
| Total expenses | 346 | 356 | 314 | 382 | 359 | 386 | 374 | 372 |
| EBITDA | 20.64 | 0.13 | 1.39 | (25.44) | 25.74 | 74.98 | 74.21 | 64.50 |
| EBITDA margin | +5.6% | +0.0% | +0.4% | -7.1% | +6.7% | +16.3% | +16.6% | +14.8% |
| Depreciation | 28.69 | 28.97 | 30.02 | 30.11 | 29.93 | 27.47 | 28.45 | 26.39 |
| Interest | 1.29 | 4.09 | 2.10 | 3.68 | 1.93 | 1.53 | 2.89 | 1.82 |
| Profit before tax | 7.38 | (10.71) | 260 | (37.83) | (1.87) | 56.03 | 61.80 | 43.37 |
| Tax | 1.85 | 4.68 | 43.71 | 2.10 | (0.02) | 4.81 | 14.91 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,412 | 1,736 | 1,442 | 1,072 | 943 | 1,124 | 904 |
| Revenue growth | -18.6% | +20.4% | +34.5% | +13.7% | -16.1% | +24.3% | - |
| Other income | 364 | 44.83 | 98.40 | 41.85 | 42.07 | 47.37 | 99.17 |
| Total expenses | 1,436 | 1,482 | 1,517 | 1,278 | 986 | 1,028 | 995 |
| Employee cost | 277 | 288 | 283 | 271 | 251 | 234 | 205 |
| EBITDA | (23.30) | 254 | (74.71) | (206) | (43.55) | 95.48 | (90.61) |
| EBITDA margin | -1.7% | +14.6% | -5.2% | -19.2% | -4.6% | +8.5% | -10.0% |
| Depreciation | 119 | 108 | 105 | 106 | 83.19 | 75.89 | 71.09 |
| Interest | 11.80 | 7.62 | 10.42 | 9.38 | 2.07 | 1.30 | 1.28 |
| Profit before tax | 209 | 183 | (92.18) | (279) | (86.74) | 65.66 | (63.81) |
| Tax | 50.47 | 19.72 | 0.00 | 20.61 | (31.32) | 11.56 | (7.50) |
| Net profit | (15.57) | 159 | (36.24) | (197) | (55.17) | 54.08 | (54.86) |
| Net profit margin | -1.1% | +9.1% | -2.5% | -18.3% | -5.9% | +4.8% | -6.1% |
| EPS (₹) | 22.58 | 23.15 | (13.09) | (42.57) | (7.87) | 7.68 | (8.00) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 14.08 | 14.08 | 14.08 | 14.08 | 14.08 | 14.08 | 14.08 |
| Reserves & surplus | 2,613 | 2,446 | 2,281 | 2,370 | 2,658 | 2,683 | 2,633 |
| Shareholders' funds (net worth) | 2,627 | 2,460 | 2,295 | 2,384 | 2,672 | 2,697 | 2,647 |
| Secured loans | 53.34 | 111 | 63.88 | 102 | 100 | 0.00 | 15.21 |
| Unsecured loans | 10.74 | 11.65 | 6.42 | 6.58 | 31.65 | 1.48 | 1.50 |
| Total debt | 64.08 | 123 | 70.30 | 108 | 132 | 1.48 | 16.71 |
| Total liabilities | 2,720 | 2,621 | 2,402 | 2,536 | 2,849 | 2,734 | 2,692 |
| Assets | |||||||
| Gross block | 1,949 | 1,926 | 1,718 | 1,691 | 1,319 | 1,128 | 1,039 |
| Net block | 1,189 | 1,275 | 1,165 | 1,236 | 963 | 850 | 829 |
| Capital work in progress | 100 | 31.03 | 122 | 148 | 494 | 568 | 331 |
| Investments | 47.49 | 45.62 | 44.08 | 40.51 | 390 | 520 | 668 |
| Inventories | 592 | 584 | 501 | 480 | 461 | 386 | 316 |
| Sundry debtors | 583 | 748 | 558 | 472 | 381 | 360 | 323 |
| Cash & bank balances | 258 | 88.63 | 129 | 157 | 99.03 | 57.59 | 205 |
| Loans & advances | 100 | 146 | 195 | 182 | 170 | 265 | 242 |
| Total current assets | 1,534 | 1,566 | 1,383 | 1,291 | 1,110 | 1,069 | 1,086 |
| Total current liabilities | 300 | 468 | 440 | 351 | 273 | 371 | 333 |
| Net working capital | 1,234 | 1,098 | 943 | 941 | 837 | 698 | 753 |
| Total assets | 2,720 | 2,621 | 2,402 | 2,536 | 2,849 | 2,734 | 2,692 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 60.58 | 126 | 156 | 94.13 | 52.60 | 203 | 302 |
| Net cash from operating activities | 52.60 | 72.29 | (41.57) | (117) | (158) | (32.61) | (41.84) |
| Net cash from investing activities | 210 | (176) | 59.61 | 241 | 104 | (72.79) | (35.59) |
| Net cash from financing activities | (70.66) | 38.26 | (48.06) | (61.76) | 95.80 | (45.07) | (21.02) |
| Net change in cash | 192 | (65.07) | (30.02) | 61.54 | 41.53 | (150) | (98.45) |
| Closing cash | 258 | 88.63 | 129 | 157 | 99.03 | 57.59 | 205 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -18.6% | +20.4% | +34.5% | +13.7% | -16.1% | +24.3% | - |
| EBITDA growth | -109.2% | +439.8% | +63.7% | -372.0% | -145.6% | +205.4% | - |
| PBT growth | +14.6% | +9998.0% | +67.0% | -221.7% | - | +9998.0% | -221.8% |
| Net income growth | -109.8% | +537.5% | +81.6% | -256.2% | -202.0% | +198.6% | - |
| Revenue CAGR (3Y) | +9.6% | +22.6% | +8.7% | +5.8% | -0.9% | +19.1% | +16.2% |
| EBITDA CAGR (3Y) | -51.6% | - | - | +31.4% | -10.5% | - | +16.0% |
| Profitability & leverage | |||||||
| Net income margin | +11.3% | +9.4% | -6.4% | -27.9% | -5.9% | +4.8% | -6.2% |
| Return on capital employed | -0.1% | +7.6% | -1.1% | -5.9% | -3.0% | +2.5% | -2.3% |
| Return on net worth | -0.6% | +6.9% | -1.6% | -7.8% | -2.1% | +2.0% | -2.1% |
| Debt / equity | 0.04 | 0.04 | 0.04 | 0.05 | 0.02 | 0.00 | 0.00 |
| Long-term debt / equity | 0.02 | 0.02 | 0.02 | 0.03 | 0.02 | 0.00 | 0.00 |
| Interest cover | -8.29 | 5.24 | -5.78 | -3.01 | -1.63 | 6.64 | -0.79 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.73 | 0.95 | 0.85 | 0.71 | 0.77 | 1.04 | 0.91 |
| Inventory turnover | 2.40 | 3.20 | 2.94 | 2.28 | 2.23 | 3.20 | 3.07 |
| Debtors turnover | 2.12 | 2.66 | 2.80 | 2.51 | 2.54 | 3.29 | 2.76 |
| EPS (₹) | 22.58 | 23.15 | (13.09) | (42.57) | (7.87) | 7.68 | (8.00) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| Book value per share (₹) | 373.17 | 349.40 | 325.94 | 338.65 | 379.52 | 383.11 | 375.99 |
To see the full year-wise statements and ratios of Unichem Laboratories Limited, buy the company report.
Board of directors of Unichem Laboratories Limited
Unichem Laboratories has 6 current directors and 16 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Prakash Amrut Mody | Director | 01 Jul 2008 | 18 Years 3 Months | Current |
| Swati Arvind Patankar Also directs: Ipca Laboratories Limited | Additional Director | 05 Feb 2026 | 0 Years 8 Months | Current |
| Arun Lalchand Todarwal Also directs: Arun Todarwal & Associates LLP, Arun Todarwal & Co LLP, Laxmi Organic Industries Limited and 5 more | Director | 05 Feb 2024 | 2 Years 8 Months | Current |
| Anand Trimbak Kusre | Director | 05 Feb 2024 | 2 Years 8 Months | Current |
| Pranay Premchand Godha | Director | 10 Aug 2023 | 3 Years 2 Months | Current |
| Pabitrakumar Kalipada Bhattacharyya Also directs: Krebs Biochemicals and Industries Limited | Managing Director | 10 Aug 2023 | 3 Years 2 Months | Current |
Peer comparison
Unichem Laboratories Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Aarti Drugs Limited | ₹2,403.39 Cr (FY 2025) | -5.0% | Thane, Maharashtra, India | |||
| Centrient Pharmaceuticals India Private Limited | ₹2,240.1 Cr (FY 2025) | 8.0% | Toansa, Punjab, India | |||
| Marksans Pharma Limited | ₹2,227.83 Cr (FY 2024) | 17.0% | Mumbai, Maharashtra, India | |||
| Unichem Laboratories Limitedthis company | ₹2,201.85 Cr (FY 2026) | ₹81.89 Cr | 3.7% | 4.3% | 3,635 | Mumbai, Maharashtra, India |
| Merck Life Science Private Limited | ₹2,200.06 Cr (FY 2025) | 7.0% | Mumbai, Maharashtra, India | |||
| FDC Limited | ₹2,198.78 Cr (FY 2025) | 8.0% | Mumbai, Maharashtra, India | |||
| Iol Chemicals and Pharmaceuticals Limited | ₹2,101.62 Cr (FY 2025) | -3.0% | Barnala, Punjab, India | |||
| Tianish Laboratories Private Limited | ₹2,059.53 Cr (FY 2024) | Hyderabad, Telangana, India | ||||
| Caplin Point Laboratories Limited | ₹2,033.9 Cr (FY 2025) | 15.0% | Chennai, Tamil Nadu, India | |||
| Pfizer Healthcare India Private Limited | ₹1,981.45 Cr (FY 2025) | 4.0% | Chennai, Tamil Nadu, India | |||
| MSN Life Sciences Private Limited | ₹1,961.87 Cr (FY 2024) | 54.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Unichem Laboratories Limited, buy the company report.
Auditor
Unichem Laboratories Limited is audited by N. A. Shah Associates LLP for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| N. A. Shah Associates LLP | FY 2025 | 116560W/W100149 |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 70.20%, foreign institutional investors hold 0.90%, domestic institutional investors hold 10.50% and retail and other public shareholders hold 18.40%.
Sep 2026
QUARTER
70.20% Promoters
10.50% DII (Domestic Institutional)
0.90% FII (Foreign Institutional)
18.40% Retail & Others
Promoter holding - history
Now 70.20% · Sep 2026High 70.20% · Dec 2025Low 70.20% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 70.20% | 70.20% | 70.20% | 70.20% |
| Public | 29.80% | 29.80% | 29.80% | 29.80% |
Charges & borrowings
Open charges
₹236 Cr
Satisfied charges
₹249.07 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 20 Jun 2025 | 101119422 | Citi Bank N.A. | ₹30 Cr | Open | |
| 24 Jan 2025 | 101041700 | Citi Bank N.A. | ₹51 Cr | Open | |
| 04 Jan 2022 | 100524009 | Others | ₹30 Cr | Open | |
| 31 May 2019 | 100269504 | Others | ₹125 Cr | Open | |
| 28 Feb 2020 | 100327424 | Axis Bank Limited | ₹30 Cr | Satisfied |
To see the full charge records of Unichem Laboratories Limited, buy the company report.
Total charge records: 54 View all charges
Deals & funding
Unichem Laboratories Limited has 14 deals on record (9 market trades, 2 secondary share transfers, 2 acquisitions), with disclosed funding of ₹56.32 Cr; the latest was in July 2026.
Total deals
14
Market trades
9
Secondary share transfers
2
Acquisitions
2
Funding round
1
Disclosed funding
₹56.32 Cr
Deals on record (5 of 14)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jun 2026 | Market trade | ₹260.33 Cr | Buyer: NK Securities Research Private Limited , Junomoneta Finsol Private Limited , Microcurves Trading Private Limited Seller: NK Securities Research Private Limited , Junomoneta Finsol Private Limited , Microcurves Trading Private Limited |
| Aug 2023 | Market trade | ₹945.35 Cr | Buyer: Ipca Laboratories Limited Seller: an individual |
| Apr 2023 | Secondary share transfer | Undisclosed | Buyer: Ipca Laboratories Limited Seller: an individual |
| Feb 2018 | Market trade | ₹40.23 Cr | Buyer: SMC Global Securities Limited Seller: Nordea 1 Sicav Indian Equity Fund N2239Lua, SMC Global Securities Limited |
| Nov 2017 | Acquisition | ₹3,600 Cr | Buyer: Torrent Pharmaceuticals Ltd Seller: Unichem Laboratories Limited |
To see the full deal history of Unichem Laboratories Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Unichem Laboratories Limited has 263 court cases on record: 169 filed by Unichem Laboratories, 94 filed against it. 41 cases are pending and 222 are disposed.
Total cases
263
Filed by the company
169
Filed against the company
94
Pending
41
Disposed
222
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 154 | 60 | 22 |
| District courts | 89 | 26 | 17 |
| Supreme Court | 17 | 5 | 0 |
| NCLAT | 2 | 2 | 2 |
| NCLT | 1 | 1 | 0 |
Cases on record (5 of 263)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Bombay High Court | Interim or miscellaneous application | Filed against the company by Torrent Pharmaceuticals Limited and 1 other | Pending |
| High Court, UTTARPRADESH | Court case (FAPL) | Filed by the company against M/S Indian Oil Corporation Ltd. | Pending |
| District court, Kolhapur, Maharashtra | Court case (Civil M.A.) | Filed by the company against Govind Poy Oxygen Ltd Through Maruti Laxaman Patil and 1 other | Pending |
| High Court, MAHARASHTRA | Court case (COMMP) | Filed against the company by Eris Lifesciences Pvt. Ltd. | Pending |
| High Court, MAHARASHTRA | Court case (COMMP) | Filed against the company by Walter Bushnell Pvt Ltd and 2 Ors and 2 others | Pending |
To see the full case history of Unichem Laboratories Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Unichem Laboratories Limited was last rated by Icra on 25 Nov 2021.
| Rating agency | Rated on | Rating |
|---|---|---|
| Icra | 25 Nov 2021 |
To see the full credit ratings and regulatory alerts of Unichem Laboratories Limited, buy the company report.
MSME payment delays
Unichem Laboratories Limited has 30 MSME Form 1 returns on record between 2014 and 2024, listing 197 overdue payments to 63 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 63)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier | |||
| FSP Technologies |
To see the full MSME payment records of Unichem Laboratories Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Unichem Laboratories has 1 associated company. This group structure data is as of FY 2025. The table lists each entity with its relationship and holding.
1
Associated companies
Employees & EPFO
Unichem Laboratories Limited has a workforce of 3,635 employees on its EPFO records as of Sep 25, 2025, across 8 active EPFO establishments.
Employee count
3,635
Active EPFO establishments
8
Employee growth
4.91%
GST
Unichem Laboratories has 26 GST registrations: 6 active and 20 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
26
Active
6
Cancelled / inactive
20
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACU0551B1ZW | Maharashtra | Active | 01 Jul 2017 |
| 27AAACU0551B2ZV | Maharashtra | Active | 21 Jul 2017 |
| 02AAACU0551B2Z7 | Himachal Pradesh | Active | 01 Jul 2017 |
| 09AAACU0551B1ZU | Uttar Pradesh | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Unichem Laboratories Limited, buy the company report.
Recent activity
Unichem Laboratories Limited has 30 board changes on record since 1979: 19 appointments and 11 cessations. The latest: Swati Arvind Patankar was appointed as Additional Director on 05 Feb 2026.
Filing
Unichem Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
Appointed
Swati Arvind Patankar was appointed as Additional Director.
Charges
A charge with Others of Rs. 125.00 Cr registered on 31 May 2019 with Charge ID 100269504 was modified on 14 Jan 2026.
AGM
Unichem Laboratories Limited last Annual general meeting of members was held on 04 Aug 2025 as per latest MCA records.
Charges
A charge registered on 28 Feb 2020 via Charge ID 100327424 with Axis Bank Limited was fully satisfied on 17 Jul 2025.
Charges
A charge with Citi Bank N.A. amounted to Rs. 30.00 Cr with Charge ID 101119422 was registered on 20 Jun 2025.
Charges
A charge with Citi Bank N.A. amounted to Rs. 51.00 Cr with Charge ID 101041700 was registered on 24 Jan 2025.
Charges
A charge registered on 16 Jul 2016 via Charge ID 100040728 with Bank Of India was fully satisfied on 07 Aug 2024.
Charges
A charge registered on 23 Jan 2018 via Charge ID 100154071 with Citi Bank N.A. was fully satisfied on 19 Jun 2024.
Ceased
Anand Yashavant Mahajan ceased to be Director.
Ceased
Prafulbhai Anubhai Shah ceased to be Director.
Ceased
Prafull D Sheth ceased to be Director.
147 earlier events are in the company report.
News
Unichem Laboratories: USFDA inspection at Goa formulation facility concludes with 5 observations related to procedural enhancements; co to respond within 15 days.
Unichem Laboratories: Company Hit with ₹87.07 Crore CGST Penalty, Aims to Appeal Decision.
Frequently asked questions
Unichem Laboratories is an active public limited company based in Mumbai, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 22 August 1962 (64+ years old) and is registered under CIN L99999MH1962PLC012451. Listed on BSE: 506690 and NSE: UNICHEMLAB.
Unichem Laboratories reported revenue of ₹2,201.85 Cr for FY 2025-26 (up 4.3% YoY) based on consolidated financials.
Unichem Laboratories has 6 current directors:
- Pabitrakumar Kalipada Bhattacharyya - Managing Director
- Prakash Amrut Mody - Director
- Swati Arvind Patankar - Additional Director
- Arun Lalchand Todarwal - Director
- Anand Trimbak Kusre - Director
- Pranay Premchand Godha - Director
The latest financial statements of Unichem Laboratories on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 04 August 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Unichem Laboratories is 27AAACU0551B1ZW, registered in Maharashtra. The company has 26 GST registrations in all, of which 6 are active and 20 are cancelled or inactive. Other active GSTINs include 27AAACU0551B2ZV (Maharashtra), 02AAACU0551B2Z7 (Himachal Pradesh), 09AAACU0551B1ZU (Uttar Pradesh).
The CIN (Corporate Identification Number) of Unichem Laboratories is L99999MH1962PLC012451. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Unichem Laboratories is a listed company as per MCA records. Its shares are listed on both BSE (code: 506690) and NSE (symbol: UNICHEMLAB).
Unichem Laboratories has 263 court cases on record: 169 filed by the company and 94 filed against it. 41 are pending. Most are in the high courts.
Unichem Laboratories was incorporated on 22 August 1962, making it 64+ years old. It is registered with the Registrar of Companies, Mumbai.
Unichem Laboratories has 14 deals on record (9 market trades, 2 secondary share transfers, 2 acquisitions), with disclosed funding of ₹56.32 Cr; the latest was in July 2026.
The peers of Unichem Laboratories by revenue are Aarti Drugs Limited, Centrient Pharmaceuticals India Private Limited, Marksans Pharma Limited, Merck Life Science Private Limited, FDC Limited and 5 more, all in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Swati Arvind Patankar was appointed as Additional Director on 05 Feb 2026. Anand Yashavant Mahajan ceased to be Director on 31 Mar 2024. Prafulbhai Anubhai Shah ceased to be Director on 31 Mar 2024. Unichem Laboratories has 30 board changes on record in total.